Insulet upgraded by Wolfe Research with a new price target
$PODD
Medical/Dental Instruments
Health Care
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $200.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/6/2025 | $340.00 | Outperform | RBC Capital Mkts |
| 11/6/2024 | $300.00 | Outperform | Bernstein |
| 5/30/2024 | $235.00 | Buy | Redburn Atlantic |
| 5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
| 12/21/2023 | $180.00 → $238.00 | Neutral → Outperform | Robert W. Baird |
| 12/4/2023 | $185.00 → $234.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/2/2023 | $260.00 → $240.00 | Hold → Buy | Jefferies |
| 8/21/2023 | $320.00 → $219.00 | Outperform → Neutral | Robert W. Baird |
First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic targets with injections People using Omnipod 5 had significantly improved HbA1c levels (average reduction of -0.8%) compared with those using multiple daily injections with a continuous glucose monitor at the end of the three-month study period Omnipod 5 was also linked to dramatic improvements in glucose with people spending an average of +5.4 hours more per day with glucose levels in the target range without an increase in hypoglycemia Insulet Corporation (NASDAQ:PODD) (Insulet or the C
Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the "Notes"). The Notes will bear interest at an annual rate of 6.50% and will mature on April 1, 2033, unless earlier redeemed or repurchased. The closing of the private placement is expected to occur on March 20, 2025, subject to customary closing conditions. The Company estimates that the net proceeds from the Notes offering will be approximately $444.4 million, after deducting discounts and before estimated offering expenses
Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the "Notes") in a private placement. The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company's existing capped call transactions relating to the Company's existing 0.375% Convertible Senior Notes due 2026 (the "Convertible Senior Notes"), (i) to finance the redemption, repurchase, repay
RBC Capital Mkts initiated coverage of Insulet with a rating of Outperform and set a new price target of $340.00
Bernstein initiated coverage of Insulet with a rating of Outperform and set a new price target of $300.00
Redburn Atlantic initiated coverage of Insulet with a rating of Buy and set a new price target of $235.00
Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic cal
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company
Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns